The recent reimbursement and launch of Zolgensma showed Japan willing and able to approve and pay for gene therapies, and others including from Otsuka/Takara Bio are moving forward under a supportive regulatory framework.

French biotech Horama has built-up its executive team and has two potential gene therapies for retinitis pigmentosa nearing the clinic.

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.